Chi-square analysis showed no statistically significant association between EDS symptom ratings and whether or not respondents were taking CNS stimulant
medication ([chi square] = 1.776, df = 3, p = 0.6201).
At present, CNS stimulants
are most commonly prescribed in the treatment of attention deficit/hyperactivity disorder (ADHD).
The moieties of 1, 2, 4-Triazole were included in a considerable range of drug candidates, which are therapeutically promising and include anti-inflammatories, anti-anxiety compounds, sedatives, CNS stimulants
, anti-microbial [1-3] and anti-mycotic agents (e.g intraconazole, fluconazole and voriconazole) [4, 5].
Some act as CNS stimulants
which can cause an increase in respiratory rate, heart rate, blood pressure and body temperature.
The success of CNS stimulants
in promoting wakefulness has led to both dextroamphetamine and Modafinil becoming FDA-approved for alleviating symptoms of the excessive daytime sleepiness associated with narcolepsy.
These revisions were made after the FDA requested that all manufacturers of CNS stimulants
approved for ADHD add standardized language in the prescribing information about these risks.
The two other treatment options are prescription medications, which are more expensive: modafinil or CNS stimulants
(most commonly amphetamines or methylphenidate).
Use of CNS stimulants
also leads to tolerance, and they have a high potential for dependence.
People who abuse CNS stimulants
or depressants give control of their bodies to the drug, sometimes with dangerous consequences.
* Comment: Approval was based on two 4-week studies of almost 200 patients with narcolepsy; most were also on CNS stimulants
. In one study, patients on 6 g or 9 g per day of Xyrem had 10 and 16 fewer attacks per week, respectively vs.
Middle High Other Ritalin(r) 559 3,362 53.9 425 94 13 17 Bronchodilaotrs 96 209 9.3 75 11 5 Analgesics 74 97 7.1 18 37 10 Anti-hypertensives 47 319 4.5 24 10 2 9 Anti-convulsants 43 253 4.1 12 4 3 20 Anti-infectives 41 174 4.0 25 7 3 2 NSAIDS 28 34 2.7 2 17 3 Anti-depressants 24 129 2.3 12 9 3 CNS stimulants
21 137 2.0 14 5 2
-- theophylline products, caffeine, Trental, Ritalin, Cylert
On the basis of drug class, the global depression drugs market has been segmented into SSRIs, atypical antipsychotics, SNRIs, CNS stimulants
, and others.
Sudden death, stroke and myocardial infarction have occurred in patients treated with CNS stimulants
at recommended doses.